

Third Quarter 2025 Performance Summary

October 2025



TOTAL REVENUE

\$800 M +7% y/y¹

TYVASO DPI²
(treprostinil) INHALATION POWDER

TYVASO²
(treprostinil) INHALATION SOLUTION

Tyvaso²

\$478M +10% y/y

REMODULIN[®]
(treprostinil) Injection

Remodulin

\$126M -2% y/y

O.
orenitram[®]
treprostinil
EXTENDED-RELEASE TABLETS

Orenitram

\$131M +16% y/y

Unituxin[®]
(dinutuximab)
Injection

Unituxin

\$48M -22% y/y



TTM OPERATING
CASH FLOW

\$1.6 billion



CASH, CASH EQUIVALENTS,
& MARKETABLE INVESTMENTS

\$4.3 billion

Quarterly Highlights

**United
Therapeutics**
A PUBLIC BENEFIT CORPORATION

**20th consecutive
quarter of y/y
revenue growth**

TYVASO DPI²
(treprostinil) INHALATION POWDER

TYVASO²
(treprostinil) INHALATION SOLUTION

- Record DPI patient shipments
- Highest revenue quarter
- Most prescribed U.S. prostacyclin

REMODULIN[®]
(treprostinil) Injection

- Most prescribed parenteral prostacyclin in the U.S.


O.
orenitram[®]
treprostinil

- Fifteenth sequential quarter of quarterly y/y revenue growth
- Highest revenue quarter

Unituxin[®]
(dinutuximab)
Injection

- The most prescribed antibody therapy for high-risk neuroblastoma in the U.S.

Quarterly Revenue, millions USD



NASDAQ

UTHR

2024 Financials

PRODUCT REVENUE

~\$2.9 billion

REVENUE/EMPLOYEE

~\$2.2 million

FOUNDED

1996

HQ

**Research Triangle Park, NC
Silver Spring, MD**

EMPLOYEES

>1,300⁴

1. y/y = year over year. 2. Tyvaso DPI + nebulized Tyvaso. 3. CAGR = compound annual growth rate calculated from 3Q/20 to 3Q/25. 4. As of 12/31/2024

Pipeline

Development Engine Addressing Unmet Needs

	Non-Registration	Registration	Filed	Approved
--	------------------	--------------	-------	----------

Tyvaso

TETON 1 - Idiopathic Pulmonary Fibrosis - U.S. and Canada

TETON 2 - Idiopathic Pulmonary Fibrosis - ROW¹

TETON PPF - Progressive Pulmonary Fibrosis

Ralinepag

ADVANCE OUTCOMES - PAH²

Xeno, Organs, and Organ Alternatives

EVLP³/CLES⁴ - Lung Transplant

EXPAND - UKidney™ for End Stage Renal Disease⁵

EXTEND - UThymoKidney™ for End Stage Renal Disease⁵

miroliverELAP⁶ - Acute Liver Failure

Pre-clinical Xeno and Organ Alternative Programs

EXPRESS - UHeart™

ULung™

miroliver®

ULobe™

IVIVA Kidney

mirokidney®

Pipeline Spotlights

TETON 2

**Study Met
Primary Endpoint**

TETON 1

**Data Expected
1H26**

ADVANCE OUTCOMES

**Data Expected
1H26**

How We Operate

CURRENT COMMERCIAL PORTFOLIO

Tyvaso DPI
Nebulized Tyvaso
Orenitram
Remodulin
Unituxin

PAH
PH-ILD

DRUG/ DEVICE PIPELINE

Tyvaso DPI
Nebulized Tyvaso
Ralinepag
EVLP

PAH
PH-ILD
IPF
PPF
LUNG TRANSPLANT

ORGAN PIPELINE

Xenotransplantation
Autologous
Regenerative Medicine
Allogeneic
Regenerative Medicine

XENO AND
ORGAN ALTERNATIVES

Learn More



United Therapeutics'
Corporate Website



United Therapeutics'
Investor Relations Website



United Therapeutics'
LinkedIn



United Therapeutics'
Corporate Responsibility
Website

This Fact Sheet contains forward-looking statements that are subject to risks and uncertainties, which are described in greater detail at ir.unither.com/disclaimer

1. ROW = rest of world outside the U.S. and Canada. 2. PAH = pulmonary arterial hypertension. 3. EVLP = ex-vivo lung perfusion.
4. CLES = centralized lung evaluation system. 5. Registrational status pending agreement with the FDA. 6. ELAP = external liver assist product.
7. IND = investigational new drug application.